GeoVax Labs Inc. recently presented information about its new HIV vaccine at a conference in South Africa.
GeoVax Chief Scientific Officer Harriet L. Robinson presented data from the biotechnology company's latest HIV immunotherapy vaccine study.
Phase 1 of the trial was completed earlier this year. In this trial, researchers tested the safety and immunogenicity of the vaccine regimen GOVX-B11 in nine HIV patients. The patients were also taking antiretroviral drug therapy (ART). The patients stalled their ART treatments for 12 weeks in the GOVX-B11 vaccine study. After the 12 weeks, the patients restarted their ART treatments. Researchers continued studying the patients for another 6 months after the vaccine treatments concluded and ART reinstated.
Data analysts concluded that the GOVX-B11 increased cell responses that are essential for killing cells infected with HIV. The infected cells could also be harboring infection that could reactivate at any time. Unfortunately GOVX-B11 did not reduce or control re-emergence of the HIV virus that could improve immune efficiency.
GeoVax continues planning future clinical studies to continue exploring options for their HIV vaccine.
The presentation was made at the HIVR4P Conference in Cape Town, South Africa.